Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Ralph P, Insinga"'
Autor:
Richard M. Haupt, Jorma Paavonen, Nubia Muñoz, Elamin Elbasha, Darron R. Brown, Mauricio Hernandez-Avila, Marc Steben, Daron G. Ferris, Elmar A. Joura, Sepp Leodolter, Suzanne M. Garland, Laura A. Koutsky, Cosette M. Wheeler, Gonzalo Perez, Ralph P. Insinga
Editorial for This Article from Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d417ff86fc590478c93e6f95f6df3255
https://doi.org/10.1158/1055-9965.22435401
https://doi.org/10.1158/1055-9965.22435401
Autor:
Richard M. Haupt, Jorma Paavonen, Nubia Muñoz, Elamin Elbasha, Darron R. Brown, Mauricio Hernandez-Avila, Marc Steben, Daron G. Ferris, Elmar A. Joura, Sepp Leodolter, Suzanne M. Garland, Laura A. Koutsky, Cosette M. Wheeler, Gonzalo Perez, Ralph P. Insinga
Background: We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions.Methods: Women ages 16 to 23 years underwent cytology and cervical s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966d204cf1553f03de3a421309c7e53c
https://doi.org/10.1158/1055-9965.c.6514902
https://doi.org/10.1158/1055-9965.c.6514902
Autor:
Richard M. Haupt, Jorma Paavonen, Nubia Muñoz, Elamin Elbasha, Darron R. Brown, Mauricio Hernandez-Avila, Marc Steben, Daron G. Ferris, Elmar A. Joura, Sepp Leodolter, Suzanne M. Garland, Laura A. Koutsky, Cosette M. Wheeler, Gonzalo Perez, Ralph P. Insinga
Table 1A. 12, 24 and 36 month transition probabilities for incident HPV 16, 18, 31, 33, 35, 45, 52, 58 and 59 infections without adjudication of CIN lesions positive for multiple HPV types. Table 1B. 12 and 24 month transition probabilities for incid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d7c1966e4e19e3f86a4db3a36998a24
https://doi.org/10.1158/1055-9965.22435398
https://doi.org/10.1158/1055-9965.22435398
Publikováno v:
PharmacoEconomics Open
Pembrolizumab monotherapy or combination therapy is an approved treatment for various advanced non-small cell lung cancer (NSCLC) indications. We review published cost-effectiveness analyses (CEAs) of pembrolizumab as treatment for NSCLC and provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42d38cbcf62ab9d6627c2d2d04d5e5ff
https://doi.org/10.1007/s41669-020-00255-2
https://doi.org/10.1007/s41669-020-00255-2
Publikováno v:
PharmacoEconomics Open
Background Pembrolizumab monotherapy and nivolumab in combination with ipilimumab are US FDA-approved first-line (1L) regimens for patients with metastatic non-small cell lung cancer (NSCLC) without epidermal growth factor receptor or anaplastic lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46be71b9b4ff1a84966851f95fc1f833
https://pubmed.ncbi.nlm.nih.gov/34292540
https://pubmed.ncbi.nlm.nih.gov/34292540
Publikováno v:
Journal of medical economics. 24(1)
Pembrolizumab + chemotherapy substantially extends life expectancy for metastatic non-small cell lung cancer (NSCLC) patients. Its cost-effectiveness (CE) was previously evaluated based on interim trial analyses (follow-up ∼1 year). The present ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb3a5cfe8b008238b131d299f8ffc9b6
https://pubmed.ncbi.nlm.nih.gov/34098842
https://pubmed.ncbi.nlm.nih.gov/34098842
Autor:
Danny C Hsu, Monika Achra, Praveen Dhankhar, Ralph P. Insinga, Herbert H. Loong, Sheenu Chandwani, Carlos K. H. Wong, Akanksha Rai, Seng Chuen Tan, Min Huang, James M. Pellissier, Linda Kam Suet Leung, Mary Y.K. Lee
Publikováno v:
PharmacoEconomics Open
Background Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15e82e7be9d03f3302373df0c7b9d95f
https://doi.org/10.1007/s41669-019-00178-7
https://doi.org/10.1007/s41669-019-00178-7
Autor:
Kristel Vandormael, Chrysostomos Kalyvas, Ralph P. Insinga, Thomas Burke, Bilal Piperdi, Balazs Halmos, Andrew Frederickson
Publikováno v:
Cancers
Cancers, Vol 12, Iss 3648, p 3648 (2020)
Volume 12
Issue 12
Cancers, Vol 12, Iss 3648, p 3648 (2020)
Volume 12
Issue 12
Background: In the absence of head-to-head trials, this study indirectly compared the effectiveness of pembrolizumab + chemotherapy vs nivolumab + ipilimumab for the first-line treatment of metastatic stage IV NSCLC patients with PD-L1 tumor proporti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc7b4d24deb892750dd4b78a4e6e8ded
http://europepmc.org/articles/PMC7762014
http://europepmc.org/articles/PMC7762014
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 146
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1f01ab8bacd3daa6ba6b093ec5bd77
https://pubmed.ncbi.nlm.nih.gov/31655368
https://pubmed.ncbi.nlm.nih.gov/31655368
AIM The study aim was to evaluate the cost effectiveness of pembrolizumab monotherapy compared with chemotherapy as a first-line treatment for previously untreated metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd7ff2992a3bbdd95eea6127fc5de44
https://www.zora.uzh.ch/id/eprint/180512/
https://www.zora.uzh.ch/id/eprint/180512/